Heron Therapeutics (HRTX) Net Shares Issued and Repurchased (2011 - 2026)

Heron Therapeutics (HRTX) has reported Net Shares Issued and Repurchased for 16 consecutive years, with $412000.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Net Shares Issued and Repurchased fell 90.76% year-over-year to $412000.0; the trailing twelve-month figure through Mar 2026 stood at $412000.0 (down 90.76% YoY), and the FY2025 full-year result was $6.5 million, down 20.19% from the prior year.
• Net Shares Issued and Repurchased slipped to $412000.0 in Q1 2026 per HRTX's latest filing, from $6.5 million in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $16.2 million in Q4 2023 and bottomed at $313000.0 in Q1 2022.
• Historically, Net Shares Issued and Repurchased has averaged $5.5 million across 5 years, with a median of $5.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Net Shares Issued and Repurchased jumped 407.35% in 2023, then sank 90.76% in 2026.
• Over 5 years, Net Shares Issued and Repurchased stood at $5.3 million in 2022, then surged by 206.06% to $16.2 million in 2023, then sank by 49.67% to $8.2 million in 2024, then dropped by 20.19% to $6.5 million in 2025, then sank by 93.67% to $412000.0 in 2026.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $412000.0, $6.5 million, and $4.5 million for Q1 2026, Q4 2025, and Q1 2025 respectively.